DHHS Adult ARV Guidelines
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects
Potential increased risk of brexpiprazole adverse effects
Management
If coadministering in patients known to be poor CYP2D6 metabolizers, use 1/4 of brexpiprazole dose. Monitor for adverse events.
Info Source
